Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Minerva Neurosciences, Inc - Common Stock (NQ:NERV)

5.700 -0.330 (-5.47%)
Streaming Delayed Price Updated: 2:51 PM EDT, Apr 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 106,335
Open 6.120
Bid (Size) 5.680 (500)
Ask (Size) 5.700 (200)
Prev. Close 6.030
Today's Range 5.660 - 6.155
52wk Range 1.150 - 12.46
Shares Outstanding 6,993,406
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
From Minerva Neurosciences, Inc
Via GlobeNewswire

Performance

YTD
+45.4%
+45.4%
1 Month
-17.4%
-17.4%
3 Month
+40.4%
+40.4%
6 Month
+170.8%
+170.8%
1 Year
+235.3%
+235.3%

More News

Read More
News headline image
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
Top stock movements in today's session. ↗
Via Chartmill
News headline image
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
Top movers in Wednesday's session ↗
Via Chartmill
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Minerva Neurosciences Stock Hits Near 2-Year High On FDA Pathway, $200M Boost — Retail Sees FDA Catalyst ↗
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
Minerva Stock Rises After Securing $200M for Schizophrenia Drug Trial ↗
Via Benzinga
News headline image
These stocks are the most active in today's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
US Stocks Mixed; Coca-Cola Posts Upbeat Earnings ↗
Via Benzinga
News headline image
These stocks that are showing activity before the opening bell on Tuesday. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Unusual volume stocks are being observed in Wednesday's session. ↗
Via Chartmill
News headline image
Top movers in Wednesday's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Minerva Neurosciences, Inc - Common Stock publicly traded?
Yes, Minerva Neurosciences, Inc - Common Stock is publicly traded.
What exchange does Minerva Neurosciences, Inc - Common Stock trade on?
Minerva Neurosciences, Inc - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Minerva Neurosciences, Inc - Common Stock?
The ticker symbol for Minerva Neurosciences, Inc - Common Stock is NERV on the Nasdaq Stock Market
What is the current price of Minerva Neurosciences, Inc - Common Stock?
The current price of Minerva Neurosciences, Inc - Common Stock is 5.700
When was Minerva Neurosciences, Inc - Common Stock last traded?
The last trade of Minerva Neurosciences, Inc - Common Stock was at 04/01/26 02:51 PM ET
What is the market capitalization of Minerva Neurosciences, Inc - Common Stock?
The market capitalization of Minerva Neurosciences, Inc - Common Stock is 39.86M
How many shares of Minerva Neurosciences, Inc - Common Stock are outstanding?
Minerva Neurosciences, Inc - Common Stock has 40M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.